z-logo
Premium
Implications of genome‐wide association studies in cancer therapeutics
Author(s) -
Patel Jai N.,
McLeod Howard L.,
Innocenti Federico
Publication year - 2013
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.12166
Subject(s) - genome wide association study , computational biology , genetic association , biology , disease , pharmacogenetics , precision medicine , genome , bioinformatics , medicine , genetics , single nucleotide polymorphism , gene , genotype
Genome wide association studies ( GWAS ) provide an agnostic approach to identifying potential genetic variants associated with disease susceptibility, prognosis of survival and/or predictive of drug response. Although these techniques are costly and interpretation of study results is challenging, they do allow for a more unbiased interrogation of the entire genome, resulting in the discovery of novel genes and understanding of novel biological associations. This review will focus on the implications of GWAS in cancer therapy, in particular germ‐line mutations, including findings from major GWAS which have identified predictive genetic loci for clinical outcome and/or toxicity. Lessons and challenges in cancer GWAS are also discussed, including the need for functional analysis and replication, as well as future perspectives for biological and clinical utility. Given the large heterogeneity in response to cancer therapeutics, novel methods of identifying mechanisms and biology of variable drug response and ultimately treatment individualization will be indispensable.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here